Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127174412 | 12717441 | 2 | F | 2015 | 20160923 | 20160906 | 20160927 | EXP | US-JNJFOC-20160902141 | JANSSEN | 0.00 | A | F | Y | 88.45000 | KG | 20160927 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127174412 | 12717441 | 1 | SS | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | Transdermal | N | UNKNOWN;1512415P1 | 0 | MATRIX PATCH | ||||||||
| 127174412 | 12717441 | 2 | SS | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | Transdermal | N | UNKNOWN;1512415P1 | 0 | MATRIX PATCH | ||||||||
| 127174412 | 12717441 | 3 | SS | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | Transdermal | N | UNKNOWN;1512415P1 | 0 | MATRIX PATCH | ||||||||
| 127174412 | 12717441 | 4 | PS | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | Transdermal | N | UNKNOWN;1512415P1 | 19813 | MATRIX PATCH | ||||||||
| 127174412 | 12717441 | 5 | C | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Oral | D | 0 | 40 | MG | CAPSULE | QD | ||||||
| 127174412 | 12717441 | 6 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | D | 0 | 150 | MG | CAPSULE | QD | ||||||
| 127174412 | 12717441 | 7 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | D | 0 | 150 | MG | CAPSULE | QD | ||||||
| 127174412 | 12717441 | 8 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | D | 0 | 225 | MG | CAPSULE | QD | ||||||
| 127174412 | 12717441 | 9 | C | POTASSIUM | POTASSIUM | 1 | Unknown | D | 0 | 40 | MEQ | TABLET | BID | ||||||
| 127174412 | 12717441 | 10 | C | ALPRAZOLAM. | ALPRAZOLAM | 1 | Oral | D | 0 | .5 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127174412 | 12717441 | 1 | Muscle spasticity |
| 127174412 | 12717441 | 2 | Muscle spasticity |
| 127174412 | 12717441 | 3 | Pain |
| 127174412 | 12717441 | 4 | Pain |
| 127174412 | 12717441 | 5 | Depression |
| 127174412 | 12717441 | 6 | Migraine |
| 127174412 | 12717441 | 7 | Depression |
| 127174412 | 12717441 | 8 | Hypertension |
| 127174412 | 12717441 | 9 | Blood potassium decreased |
| 127174412 | 12717441 | 10 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127174412 | 12717441 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127174412 | 12717441 | Drug effect decreased | |
| 127174412 | 12717441 | Feeling abnormal | |
| 127174412 | 12717441 | Heart rate increased | |
| 127174412 | 12717441 | Hyperhidrosis | |
| 127174412 | 12717441 | Lipoma | |
| 127174412 | 12717441 | Off label use | |
| 127174412 | 12717441 | Paraesthesia | |
| 127174412 | 12717441 | Product adhesion issue | |
| 127174412 | 12717441 | Wrong technique in product usage process |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127174412 | 12717441 | 2 | 2014 | 0 | ||
| 127174412 | 12717441 | 4 | 2014 | 0 |